
Opinion|Videos|July 16, 2024
Integrating Dry Eye Care into Ophthalmic Surgery Practice
Experts discuss strategies for making dry eye care an appealing practice option for optometry students and supporting their success in this specialized field.
Advertisement
Episodes in this series
1:39 Starting Dry Eye Practice
6:00 Clinical Trials
9:00 Treatment Benefits
15:00 Revenue Generation
20:00 Dry Eye Innovations
23:00 Tailoring Treatment
Advertisement
Related to this article

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss tubeless Mobi's FDA clearance, CVS Caremark's CGM formulary shift, and a transmitter-free implant.

Aficamten's label now includes MAPLE-HCM data, in which aficamten monotherapy improved peak VO2 by 2.3 mL/kg/min more than metoprolol at 24 weeks.
Advertisement
Advertisement
Trending on HCPLive
1
Upadacitinib Response Within Days in Crohn’s Disease, With Raja Atreya, MD
2
Stepwise Chronic Spontaneous Urticaria Management, With Timothy Craig, DO
3
Ultra-Processed Food Intake Increases Risk of HF in All Phenotypes
4
Top Videos From 2026 Dermatology Meetings: 12 Expert Interviews to Watch
5

